329 related articles for article (PubMed ID: 29313215)
41. Mitochondrial DNA content as a potential marker to predict response to anthracycline in breast cancer patients.
Hsu CW; Yin PH; Lee HC; Chi CW; Tseng LM
Breast J; 2010; 16(3):264-70. PubMed ID: 20408822
[TBL] [Abstract][Full Text] [Related]
42. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
[TBL] [Abstract][Full Text] [Related]
43. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
[TBL] [Abstract][Full Text] [Related]
44. Psychometric properties and measurement equivalence of the Multidimensional Fatigue Syndrome Inventory- Short Form (MFSI-SF) amongst breast cancer and lymphoma patients in Singapore.
Chan A; Lew C; Wang XJ; Ng T; Chae JW; Yeo HL; Shwe M; Gan YX
Health Qual Life Outcomes; 2018 Jan; 16(1):20. PubMed ID: 29351803
[TBL] [Abstract][Full Text] [Related]
45. Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.
Schwentner L; Wöckel A; König J; Janni W; Blettner M; Kreienberg R; Van Ewijk R;
Eur J Cancer; 2014 Nov; 50(17):2905-15. PubMed ID: 25239681
[TBL] [Abstract][Full Text] [Related]
46. Mitochondrial DNA levels in blood and tissue samples from breast cancer patients of different stages.
Xia P; Wang HJ; Geng TT; Xun XJ; Zhou WJ; Jin TB; Chen C
Asian Pac J Cancer Prev; 2014; 15(3):1339-44. PubMed ID: 24606462
[TBL] [Abstract][Full Text] [Related]
47. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.
Martincich L; Montemurro F; De Rosa G; Marra V; Ponzone R; Cirillo S; Gatti M; Biglia N; Sarotto I; Sismondi P; Regge D; Aglietta M
Breast Cancer Res Treat; 2004 Jan; 83(1):67-76. PubMed ID: 14997056
[TBL] [Abstract][Full Text] [Related]
48. Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology.
Chen EI; Crew KD; Trivedi M; Awad D; Maurer M; Kalinsky K; Koller A; Patel P; Kim Kim J; Hershman DL
PLoS One; 2015; 10(12):e0145816. PubMed ID: 26710119
[TBL] [Abstract][Full Text] [Related]
49. Peripheral blood mitochondrial DNA content, A10398G polymorphism, and risk of breast cancer in a Han Chinese population.
Jiang H; Zhao H; Xu H; Hu L; Wang W; Wei Y; Wang Y; Peng X; Zhou F
Cancer Sci; 2014 Jun; 105(6):639-45. PubMed ID: 24703408
[TBL] [Abstract][Full Text] [Related]
50. Effects of Acupuncture on Cancer-Related Cognitive Impairment in Chinese Gynecological Cancer Patients: A Pilot Cohort Study.
Zeng Y; Cheng ASK; Song T; Sheng X; Wang S; Xie J; Chan CCH
Integr Cancer Ther; 2018 Sep; 17(3):737-746. PubMed ID: 29806502
[TBL] [Abstract][Full Text] [Related]
51. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.
Greenlee H; Crew KD; Capodice J; Awad D; Buono D; Shi Z; Jeffres A; Wyse S; Whitman W; Trivedi MS; Kalinsky K; Hershman DL
Breast Cancer Res Treat; 2016 Apr; 156(3):453-464. PubMed ID: 27013473
[TBL] [Abstract][Full Text] [Related]
52. Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline/taxane-based chemotherapy.
Vasconcelos I; Wiesske A; Schoenegg W
Breast; 2018 Aug; 40():1-3. PubMed ID: 29660543
[TBL] [Abstract][Full Text] [Related]
53. Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study.
Goldstein D; Bennett BK; Webber K; Boyle F; de Souza PL; Wilcken NR; Scott EM; Toppler R; Murie P; O'Malley L; McCourt J; Friedlander M; Hickie IB; Lloyd AR
J Clin Oncol; 2012 May; 30(15):1805-12. PubMed ID: 22508807
[TBL] [Abstract][Full Text] [Related]
54. Association between peripheral blood cells mitochondrial DNA content and severity of coronary heart disease.
Liu LP; Cheng K; Ning MA; Li HH; Wang HC; Li F; Chen SY; Qu FL; Guo WY
Atherosclerosis; 2017 Jun; 261():105-110. PubMed ID: 28242046
[TBL] [Abstract][Full Text] [Related]
55. Immediate-term cognitive impairment following intravenous (IV) chemotherapy: a prospective pre-post design study.
Khan OF; Cusano E; Raissouni S; Pabia M; Haeseker J; Bosma N; Ko JJ; Li H; Kumar A; Vickers MM; Tang PA
BMC Cancer; 2019 Feb; 19(1):150. PubMed ID: 30764801
[TBL] [Abstract][Full Text] [Related]
56. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
57. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.
Fornier MN; Modi S; Panageas KS; Norton L; Hudis C
Cancer; 2005 Oct; 104(8):1575-9. PubMed ID: 16134178
[TBL] [Abstract][Full Text] [Related]
58. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Burstein HJ; Elias AD; Rugo HS; Cobleigh MA; Wolff AC; Eisenberg PD; Lehman M; Adams BJ; Bello CL; DePrimo SE; Baum CM; Miller KD
J Clin Oncol; 2008 Apr; 26(11):1810-6. PubMed ID: 18347007
[TBL] [Abstract][Full Text] [Related]
59. Leukocyte mitochondrial DNA content: a novel biomarker associated with prognosis and therapeutic outcome in colorectal cancer.
Qu F; Chen Y; Wang X; He X; Ren T; Huang Q; Zhang J; Liu X; Guo X; Gu J; Xing J
Carcinogenesis; 2015 May; 36(5):543-52. PubMed ID: 25823896
[TBL] [Abstract][Full Text] [Related]
60. The distress thermometer predicts subjective, but not objective, cognitive complaints six months after treatment initiation in cancer patients.
Lycke M; Lefebvre T; Pottel L; Pottel H; Ketelaars L; Stellamans K; Eygen KV; Vergauwe P; Werbrouck P; Goethals L; Schofield P; Boterberg T; Debruyne PR
J Psychosoc Oncol; 2017; 35(6):741-757. PubMed ID: 28816636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
